Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Catalyst Pharmaceuticals, Inc. (CPRX) - free report >>
Immunocore Holdings PLC Sponsored ADR (IMCR) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalyst Pharmaceuticals, Inc. (CPRX) - free report >>
Immunocore Holdings PLC Sponsored ADR (IMCR) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for January 10th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 10th:
Immunocore Holdings plc (IMCR - Free Report) : This late-stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.9% over the last 60 days.
Immunocore Holdings PLC Sponsored ADR Price and Consensus
Immunocore Holdings PLC Sponsored ADR price-consensus-chart | Immunocore Holdings PLC Sponsored ADR Quote
Immunocore’s shares gained 52% over the last three months compared with the S&P 500’s advance of 8.4%. The company possesses a Momentum Score of A.
Immunocore Holdings PLC Sponsored ADR Price
Immunocore Holdings PLC Sponsored ADR price | Immunocore Holdings PLC Sponsored ADR Quote
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) : This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25.7% over the last 60 days.
Catalyst Pharmaceuticals, Inc. Price and Consensus
Catalyst Pharmaceuticals, Inc. price-consensus-chart | Catalyst Pharmaceuticals, Inc. Quote
Catalyst’s shares gained 17.4% over the last three months compared with the S&P 500’s advance of 8.4%. The company possesses a Momentum Score of A.
Catalyst Pharmaceuticals, Inc. Price
Catalyst Pharmaceuticals, Inc. price | Catalyst Pharmaceuticals, Inc. Quote
AmpriusTechnologies, Inc. (AMPX - Free Report) : This ultra-high energy density lithium-ion batteries company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.5% over the last 60 days.
Amprius Technologies, Inc. Price and Consensus
Amprius Technologies, Inc. price-consensus-chart | Amprius Technologies, Inc. Quote
Amprius’s shares gained 11.5% over the last three months compared with the S&P 500’s advance of 8.4%. The company possesses a Momentum Score of A.
Amprius Technologies, Inc. Price
Amprius Technologies, Inc. price | Amprius Technologies, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.